We examined ethnoracial differences in fatty acid binding protein (FABP)—a family of intracellular lipid carriers—and clarified FABP3 associations with gray and white matter. Relative to Mexican Americans (MAs), FABP3 was higher in Non-Hispanic Whites (NHWS, p < 0.001). Regressions revealed, independent of traditional AD markers, FABP3 was associated with neurodegeneration (B = –0.08, p = 0.003) and WMH burden (B = 0.18, p = 0.03) in MAs, but not in NHWs (ps > 0.18). Findings suggest FABP3 is related to neural health within MAs and highlight its potential as a prognostic marker of brain health in ethnoracially diverse older adults.
ChewH, SolomonVA, FontehAN (2020) Involvement of lipids in Alzheimer’s disease pathology and potential therapies. Front Physiol11, 598.
2.
LiuCC, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
3.
AndrewsSJ, Fulton-HowardB, GoateA (2020) Interpretation of risk loci from genome-wide association studies of Alzheimer’s disease. Lancet Neurol19, 326–335.
4.
O’BryantSE, JohnsonL, BalldinV, EdwardsM, BarberR, WilliamsB, DevousM, CushingsB, KneblJ, HallJ (2013) Characterization of Mexican Americans with mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis33, 373–379.
5.
GonzálezHM, TarrafW, SchneidermanN, FornageM, VásquezPM, ZengD, YoungbloodM, GalloLC, DaviglusML, LiptonRB, KaplanR, RamosAR, LamarM, ThomasS, ChaiA, DeCarliC (2019) Prevalence and correlates of mildcognitive impairment among diverse Hispanics/Latinos: Study of Latinos-Investigation of Neurocognitive Agingresults. Alzheimers Dement15, 1507–1515.
6.
SepeFN, ChiasseriniD, ParnettiL (2018) Role of FABP3 as biomarker in Alzheimer’s disease and synucleinopathies. Future Neurol13, 199–207.
7.
BjerkeM, KernS, BlennowK, ZetterbergH, WaernM, Börjesson-HansonA, ÖstlingS, KernJ, SkoogI (2016) Cerebrospinal fluid fatty acid-binding protein 3 is related to dementia development in a population-based sample of older adult women followed for 8 years. J Alzheimers Dis |bf 49, 733–741.
8.
KhanW, AguilarC, KiddleSJ, DoyleO, ThambisettyM, MuehlboeckS, SattleckerM, NewhouseS, LovestoneS, DobsonR (2015) A subset of cerebrospinal fluid proteins from a multi-analyte panel associated with brain atrophy, disease classification and prediction in Alzheimer’s disease. PloS One10, e0134368.
9.
SteinackerP, MollenhauerB, BiblM, CepekL, EsselmannH, BrechlinP, LewczukP, PoserS, KretzschmarHA, WiltfangJ (2004) Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett370, 36–39.
10.
OddoS, CaccamoA, ShepherdJD, MurphyMP, GoldeTE, KayedR, MetherateR, MattsonMP, AkbariY, LaFerlaFM (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Aβ and synaptic dysfunction. Neuron39, 409–421.
11.
PélerinH, JouinM, LallemandM-S, AlessandriJ-M, CunnaneSC, LangelierB, GuesnetP (2014) Gene expressionof fatty acid transport and binding proteins in the blood–brain barrier and the cerebral cortex of therat: Differences across development and with different DHA brain status. Prostaglandins Leukot Essent FattyAcids91, 213–220.
ChiasseriniD, ParnettiL, AndreassonU, ZetterbergH, GiannandreaD, CalabresiP, BlennowK (2010) CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer’s disease. J Alzheimers Dis22, 1281–1288.
14.
DulewiczM, Kulczyńska-PrzybikA, SłowikA, BorawskaR, MroczkoB (2021) Fatty acid binding protein 3(FABP3) and Apolipoprotein E4 (ApoE4) as lipid metabolism-related biomarkers of Alzheimer’s disease. J ClinMed10, 3009.
BabulalGM, QuirozYT, AlbensiBC, Arenaza-UrquijoE, AstellAJ, BabiloniC, Bahar-FuchsA, BellJ, BowmanGL, BrickmanAM (2019) Perspectives on ethnic and racial disparities in Alzheimer’s disease and related dementias: Update and areas of immediate need. Alzheimers Dement15, 292–312.
17.
BrickmanAM, SchupfN, ManlyJJ, LuchsingerJA, AndrewsH, TangMX, ReitzC, SmallSA, MayeuxR, DeCarliC, BrownTR (2008) Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan. Arch Neurol65, 1053–1061.
18.
MatthewsKA, XuW, GagliotiAH, HoltJB, CroftJB, MackD, McGuireLC (2019) Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015-2060) in adults aged > /=65 years. Alzheimers Dement15, 17–24.
19.
FilshteinTJ, DuggerBN, JinLW, OlichneyJM, FariasST, Carvajal-CarmonaL, LottP, MungasD, ReedB, BeckettLA, DeCarliC (2019) Neuropathological diagnoses of demented Hispanic, Black, and Non-Hispanic White decedents seen at an Alzheimer’s disease center. J Alzheimers Dis68, 145–158.
20.
O’BryantSE, XiaoG, EdwardsM, DevousM, GuptaVB, MartinsR, ZhangF, BarberR (2013) Biomarkers of Alzheimer’s disease among Mexican Americans. J Alzheimers Dis34, 841–849.
21.
O’BryantSE, ZhangF, PetersenM, HallJR, JohnsonLA, YaffeK, MasonD, BraskieM, BarberRA, RissmanRA (2022) A blood screening tool for detecting mild cognitive impairment and Alzheimer’s disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research. Alzheimers Dement18, 77–87.
O’BryantSE, JohnsonLA, BarberRC, BraskieMN, ChristianB, HallJR, HazraN, KingK, KothapalliD, LargeS (2021) The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics. Alzheimers Dement (Amst)13, e12202.
24.
O’BryantSE, GuptaV, HenriksenK, EdwardsM, JerominA, ListaS, BazenetC, SoaresH, LovestoneS, HampelH, MontineT, BlennowK, ForoudT, CarrilloM, Graff-RadfordN, LaskeC, BretelerM, ShawL, TrojanowskiJQ, SchupfN, RissmanRA, FaganAM, OberoiP, UmekR, WeinerMW, GrammasP, PosnerH, MartinsR, StarB, groupsBw (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement11, 549–560.
25.
EckelRH, GrundySM, ZimmetPZ (2005) The metabolic syndrome. Lancet365, 1415–1428.
26.
JackCR, WisteHJ, TherneauTM, WeigandSD, KnopmanDS, MielkeMM, LoweVJ, VemuriP, MachuldaMM, SchwarzCG (2019) Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA321, 2316–2325.
27.
SchmidtP, GaserC, ArsicM, BuckD, FörschlerA, BertheleA, HoshiM, IlgR, SchmidVJ, ZimmerC (2012) An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage59, 3774–3783.
28.
WardJB, GartnerDR, KeyesKM, FlissMD, McClureES, RobinsonWR (2019) How do we assess a racial disparity in health? Distribution, interaction, and interpretation in epidemiological studies. Ann Epidemiol29, 1–7.
29.
KimY, KimS-Y, KimY, KwonHJ, rok KimJ, LeeHK, YooK-D (2014) Polymorphisms of the heart-type fatty acid-binding protein as a prognostic factor in patients with atherosclerosis. Ann Clin Lab Sci44, 67–72.
30.
OwadaY (2008)Fatty acid binding protein: Localization and functional significance in the brain. Tohoku J Exp Med214, 213–220.
31.
MurphyEJ, OwadaY, KitanakaN, KondoH, GlatzJF (2005) Brain arachidonic acid incorporation is decreased in heart fatty acid binding protein gene-ablated mice. Biochemistry44, 6350–6360.
32.
ForetJT, DekhtyarM, BirdsillAC, TanakaH, HaleyAP (2021) Metabolic syndrome components moderate the association between executive function and functional connectivity in the default mode network. Brain Imaging Behav15, 2139–2148.
33.
BrosseronF, KleemannK, KolbeCC, SantarelliF, Castro-GomezS, TacikP, LatzE, JessenF, HenekaMT (2021) Interrelations of Alzheimer’s disease candidate biomarkers neurogranin, fatty acid-binding protein 3 and ferritin to neurodegeneration and neuroinflammation. J Neurochem157, 2210–2224.
